rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    JAZZ
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Jazz Pharmaceuticals at jefferies global healthcare conference: growth broadens
      Nov 17Investing.comJAZZJEF
      PJP: Healthcare Sector Dashboard For November

      Analyst sees Invesco Pharmaceuticals ETF as a long-term or tactical option; it beat XLV in the past year but lagged from July 2015 to July 2025.

      Nov 17Seeking AlphaJAZZ
      CrowdStrike To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
      Nov 15BenzingaJAZZ
      Piper Sandler raises Jazz Pharmaceuticals price target on Ziihera outlook
      Nov 12Investing.comJAZZ
      At Jazz Pharmaceuticals, Bruce C Cozadd Chooses To Exercise Options, Resulting In $9.46M
      Nov 11BenzingaJAZZ
      Ocular Therapeutix (OCUL) reports earnings tomorrow: what to expect

      Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be reporting results this Monday morning. Here’s what to look for.

      Nov 10Yahoo FinanceJAZZOCUL
      Jazz Pharmaceuticals Rings the Closing Bell

      About This EventJazz Pharmaceuticals (Nasdaq: JAZZ), a global biopharma company whose purpose is to innovate to transform the lives of patients and their families, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Renee Gala, President and Chief Executive Officer, rings the Closing Bell.

      Nov 9NasdaqJAZZ
      Bernstein cuts Jazz Pharmaceuticals stock price target on Zepzelca outlook
      Nov 9Investing.comJAZZ
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP) and Travere Therapeutics (TVTX)

      Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

      Nov 4The Globe and MailJAZZTVTXINSP
      Jazz Pharmaceuticals (JAZZ) Stock Jumps On Q2 Earnings Turnaround

      Jazz Pharmaceuticals entered this earnings season trading like a problem child with potential, well below many fair value models and still dealing with the memory of a large one off loss. Q2 2026 results landed with a jolt. The stock rose 7.2% in regular trading to US$229.97 as investors reacted to a mix of strong Q3 revenue of US$1.24b and a much cleaner trailing earnings picture at 12 month basic earnings per share of US$15.25. Like the cleaner earnings profile at Jazz Pharmaceuticals but...

      Nov 3Yahoo FinanceJAZZ
      Jazz Pharmaceuticals PLC (JAZZ) (Q3 2026) Earnings Call Highlights: Record $1. ...
      Nov 3Yahoo FinanceJAZZ
      Jazz climbs as 2026 revenue guidance boosted

      Jazz Pharmaceuticals jumps after raising its 2026 revenue forecast and topping Q3 sales estimates. Read more here.

      Nov 3Seeking AlphaJAZZ
      Jazz Pharmaceuticals plc Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceJAZZ
      RBC Raises Price Target on Jazz Pharmaceuticals to $305 From $296, Keeps Outperform Rating

      Jazz Pharmaceuticals (JAZZ) has an average rating of buy and mean price target of $299.81, according

      Nov 3Yahoo FinanceJAZZ
      Baird reiterates Jazz Pharmaceuticals stock rating on sleep franchise
      Nov 3Investing.comJAZZ
      Jazz: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceJAZZ
      Jazz Pharmaceuticals (JAZZ) Will Present Phase 3 And Phase 2 Brain Cancer Data
      Nov 3Yahoo FinanceJAZZ
      Jazz Pharmaceuticals (JAZZ) Could Be 27% Undervalued As Record Revenue Lifts Outlook
      Nov 3Yahoo FinanceJAZZ
      Jazz Pharmaceuticals Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceJAZZ
      Does Earnings Beat Change The Bull Case For Jazz Pharmaceuticals Stock (JAZZ)?
      Nov 3Yahoo FinanceJAZZ
      Jazz Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 2BenzingaJAZZ
      Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Nov 2Yahoo FinanceJAZZ
      Jazz Pharmaceuticals earnings missed by $10.18, revenue topped estimates
      Nov 2Investing.comJAZZ
      Jazz Pharmaceuticals Q3 Swings to Adjusted Loss, Revenue Rises
      Nov 2Yahoo FinanceJAZZ
      Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates

      Jazz (JAZZ) delivered earnings and revenue surprises of +5.13% and +2.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 2Yahoo FinanceJAZZ
      Jazz Pharmaceuticals earnings in focus after oncology approval
      Nov 2Investing.comJAZZ
      Jazz Pharmaceuticals (NASDAQ:JAZZ) surprises with Q3 2026 sales, full-year sales guidance is optimistic

      Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

      Nov 2The Globe and MailJAZZ
      What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
      Nov 1Yahoo FinanceJAZZ
      With Setara, the team behind Actio opens its second act
      Oct 30Yahoo FinanceJAZZ
      Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Jazz Pharmaceuticals (JAZZ) and Repligen (RGEN)

      Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailJAZZRGENIQV
      Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine | The Motley Fool

      Jazz Pharmaceuticals' strategy is starting to pay dividends.

      Oct 27The Motley FoolJAZZ
      Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
      Oct 27Yahoo FinanceJAZZRARE
      Jazz Pharmaceuticals Expects $755 Million Charge to Impact Q3 Earnings
      Oct 26Yahoo FinanceJAZZ
      Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
      Oct 26Yahoo FinanceJAZZ
      TD Cowen Names Top Biotech Stocks for Q4 Amid Market Volatility
      Oct 22Investing.comJAZZ
      Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
      Oct 21Yahoo FinanceAXSMJAZZ
      Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?
      Oct 16Yahoo FinanceJAZZ
      Ziihera’s FDA Win and Leadership Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ)
      Oct 16Yahoo FinanceJAZZ
      Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing Earnings Story

      Jazz Pharmaceuticals is transforming beyond oxybate reliance, with growth across sleep medicine, epilepsy, and oncology portfolios. See why JAZZ stock is a Buy.

      Oct 15Seeking AlphaJAZZ
      Jazz Pharmaceuticals gets Cramer’s vote of confidence
      Oct 14TheStreetJAZZ
      Jazz Pharmaceuticals gets Cramer's vote of confidence

      Jim Cramer backed the tumbling pharma stock, even though JAZZ shares have fallen during the past month.

      Oct 13Yahoo FinanceJAZZ
      Jim Cramer Gives Green Light To This Health Care Stock - Jazz Pharmaceuticals (NASDAQ:JAZZ)

      Cramer warns against Apple Hospitality if rates hit 6%, prefers Vylor over Corteva, backs Jazz, and notes SpaceX may bid for EchoStar.

      Oct 12BenzingaJAZZAPLE
      Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'

      "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

      Oct 9CNBCJAZZ
      BofA Securities Adjusts Jazz Pharmaceuticals Price Target to $313 From $307, Maintains Buy Rating
      Oct 9Yahoo FinanceJAZZ
      RBC Trims Price Target on Jazz Pharmaceuticals to $296 From $299, Keeps Outperform Rating
      Oct 8Yahoo FinanceJAZZ
      Jazz Pharmaceuticals Insider Sold Shares Worth $1,381,980, According to a Recent SEC Filing
      Oct 5Yahoo FinanceJAZZ
      Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks

      As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

      Sep 30Yahoo FinanceJAZZ
      Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE)

      Nuvation Bio NUVB) stock and Jazz Pharmaceuticals (JAZZ) stock gain as Citi issues new Buy ratings on the firms based on their cancer treatments. Read more here.

      Sep 30Seeking AlphaJAZZNUVB
      Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target
      Sep 30Yahoo FinanceJAZZ
      Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)

      Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailJAZZLEGNOCGN

      This is the newest page. Registered accounts read further back.